Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 4:10:470.
doi: 10.3389/fcimb.2020.00470. eCollection 2020.

Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection

Affiliations

Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection

Tao Li et al. Front Cell Infect Microbiol. .

Abstract

Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.

Keywords: COVID-19; SARS-CoV-2; colloidal gold immunochromatography; diagnostic value; nucleocapsid protein.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT images of 4 patients whose N protein is consistently negative, (A,B), CT images of Patient 3 1–3 days after admission; (C,D), CT images of Patient 32 1–3 days after admission; (E,F), CT images of Patient 33 1–3 days after admission; (G,H), CT images of Patient 40 1–3 days after admission.
Figure 2
Figure 2
ROC curve of serum SARS-COV-2 N protein, area under the ROC curve is 0.9756, 95% confidence interval (CI) is 0.9485 to 1.000, p-value is lower 0.0001, sensitivity and specificity are 92% (95% CI 81.16 to 96.85%) and 96.84% (95% CI 95.17 to 97.15%), respectively. The best CUT-OFF value is 1.850 pg/mL.
Figure 3
Figure 3
Distribution of N Protein concentration result of sample data using the CUT-OFF value equaling to 10, Group A (Nucleic Acid Positive + Antibody Negative, N = 50), Group B (Nucleic Acid Positive + Antibody Positive, N = 37), Control Group (non-SARS-COV-2 infection, N = 633).

Similar articles

Cited by

References

    1. Abduljalil J. M. (2020). Laboratory diagnosis of SARS-CoV-2: available approaches and limitations. N. Microb. N. Infect. 36:100713. 10.1016/j.nmni.2020.100713 - DOI - PMC - PubMed
    1. Cai X. F., Chen J., Li Hu J., Long Q. X., Deng H. J., Liu P., et al. . (2020). A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019 (COVID-19). J Infect Dis. jiaa243. 10.1093/infdis/jiaa243 - DOI - PMC - PubMed
    1. Chan J. F., Yip C. C., To K. K., Tang T. H., Wong S. C., Leung K. H., et al. . (2020). Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. J. Clin. Microbiol. 58:e00310-20. 10.1128/JCM.00310-20 - DOI - PMC - PubMed
    1. Cheng Z., Lu Y., Cao Q., Qin L., Pan Z., Yan F., et al. . (2020). Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China. Am. J. Roentgenol. 215, 121–126. 10.2214/AJR.20.22959 - DOI - PubMed
    1. Corman V. M., Landt O., Kaiser M., Molenkamp R., Meijer A., Chu D. K., et al. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25:2000045 10.2807/1560-7917.ES.2020.25.3.2000045 - DOI - PMC - PubMed

Publication types

MeSH terms